🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to researchers.

An International Health Concern

The sexually transmitted infection are increasing globally, with data suggesting over 82 million instances annually. Notably increased rates are observed in the African continent and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the context of rising global incidence, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Public health authorities are increasingly worried about the surge in drug-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Gain Authorization

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Experts believe that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, was also approved in concurrent days. This medication, which is also used to treat UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a new, not-for-profit approach for medication research. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This milestone marks a huge turning point in the management of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Testing Outcomes and Global Access

As per findings released by a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which combines two antibiotics. The study enrolled nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the authority to license and sell the drug in many regions with limited resources.

Doctors on the front lines have shared hope. Access to a easy-to-administer therapy such as this is hailed as a "revolutionary step" for managing the epidemic. This is considered vital to alleviate the strain of the disease for people and to halt the transmission of extremely resistant gonorrhoea worldwide.